The company still ended the quarter on a pile of cash to support its R&D efforts. Toronto-based Cybin Inc. (NYSE: CYBN) reported financials for its fiscal second quarter 2025 ending Sept. 30, with higher R&D costs from its clinical programs. The company also announced it has initiated a phase 3 program evaluating its psilocin-based CYB003 […]
Relmada also told investors that it didn’t think it had enough money to last a year from now. Relmada Therapeutics (Nasdaq: RLMD) provided a corporate update and announced preliminary and unaudited financial results for the third quarter ending Sept. 30. The company does not have revenue to report as of yet. Net loss for the […]
Compass Pathways (NASDAQ: CMPS) plans to cut about 30% of its workforce and halt early-stage research programs as the firm focuses resources on completing late-stage trials of its lead COMP360 program. The London-based company announced the restructuring alongside third-quarter financial results that showed a widening net loss of $38.5 million versus $33.4 million a year […]
Oregon, the first state to fully legalize psychedelics, will roll out therapy this year, with the rest of the country watching closely for cautionary tales and of course, success stories. Not to be outdone, NY and California have also pushed for similar proposals. Both proposals would relax laws around certain hallucinogens, including psilocybin, ibogaine and DMT, […]
Oregon, the first state to fully legalize psychedelics, will roll out therapy this year, with the rest of the country watching closely for cautionary tales and of course, success stories. Not to be outdone, NY and California have also pushed for similar proposals. Both proposals would relax laws around certain hallucinogens, including psilocybin, ibogaine and DMT, […]
